-
P Zarb,
B Coignard,
J Griskeviciene, A Muller,
V Vankerckhoven,
K Weist,
M M Goossens,
S Vaerenberg,
S Hopkins,
B Catry,
D L Monnet,
H Goossens,
C Suetens,
National Contact Points for the ECDC pilot point prevalence survey,
Hospital Contact Points for the ECDC pilot point prevalence survey
Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 11/2012; 17(46-Volume 17, Issue 46, 15 November 2012). · 6.15 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Clin Microbiol Infect 2012; 18: E389-E395 ABSTRACT: The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99 053 patients, 29 324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40 878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use.
Clinical Microbiology and Infection 07/2012; 18(10):E389-E395. · 4.54 Impact Factor
-
Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 11/2007; 12(10):E071011.1. · 6.15 Impact Factor
-
International Journal of Antimicrobial Agents. 29:S297-S298.
